Ponezumab Biosimilar - Research Grade

Human

APP

>1mg/ml

Human IgG2(A330S/P331S)-Kappa

Aducanumab Biosimilar - Research Grade (ICH5008), Gantenerumab Biosimilar - Research Grade (ICH5009), Bapineuzumab Biosimilar - Research Grade (ICH5140), Lecanemab Biosimilar - Research Grade (ICH5219), Crenezumab Biosimilar - Research Grade (ICH5454), Donanemab Biosimilar - Research Grade (ICH5487), Remternetug Biosimilar - Research Grade (ICH5815), Sabirnetug Biosimilar - Research Grade (ICH5842), Solanezumab Biosimilar - Research Grade (ICH5871), Usilnetug Biosimilar - Research Grade (ICH5963)

https://www.imgt.org/mAb-DB/

ICH3002

P05067

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ponezumab, supplied strictly for research use only. Ponezumab is a humanized monoclonal antibody directed against the amyloid-beta (Abeta) peptide, a proteolytic fragment released from the amyloid-beta precursor protein (APP; UniProt P05067). It was investigated as a passive-immunotherapy candidate for Alzheimer disease, engineered to bind soluble Abeta and promote peripheral clearance. The research-grade analog reproduces the antigen-binding specificity of the originator so that laboratories can use it as a defined tool reagent rather than as a clinical drug. It is useful as a positive control and reference binder in Abeta ELISA, immunodepletion, and neutralization assays; as a benchmarking reagent in comparability, epitope-mapping, and antibody-engineering work; and as a standardized input for aggregation and clearance studies in cell-based and preclinical systems. It carries an engineered effector-attenuated Fc (Human IgG2 with A330S/P331S), matching the low-ADCC/CDC design of the originator. Material is offered at research grade with low endotoxin and in bulk milligram-to-gram quantities. It is not the clinical drug and is not for human or veterinary use. The amyloid-beta precursor protein (APP; UniProt P05067) is a single-pass type I transmembrane glycoprotein broadly expressed in neurons and other tissues, where it contributes to cell adhesion, synapse formation, and signaling. Sequential proteolysis governs its fate: alpha-secretase within the amyloidogenic region yields soluble sAPP-alpha, whereas beta-secretase (BACE1) followed by gamma-secretase liberates the amyloid-beta (Abeta) peptides, principally Abeta40 and the more aggregation-prone Abeta42. These peptides self-associate into soluble oligomers and fibrils that deposit as extracellular plaques, a defining neuropathological feature of Alzheimer disease. Ponezumab does not target the full-length APP holoprotein but rather binds the free C-terminus of the Abeta40 peptide, a neo-epitope exposed after gamma-secretase cleavage. This specificity underlies its intended mechanism of engaging soluble Abeta to facilitate clearance while minimizing binding to intact membrane-anchored APP.

Amyloid-beta precursor protein, amyloid precursor protein

Detects human APP

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Ponezumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Ponezumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ponezumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ponezumab that binds human APP.